Fluconazole in transplant recipients: options and limitations

Area of Science:

• Medical Mycology
• Infectious Diseases
• Pharmacology

Background:

• Fluconazole is a first-line antifungal for candidal infections due to efficacy, oral availability, and low toxicity.
• Its use in transplant patients for prophylaxis and empirical treatment presents challenges.
• Concerns include azole resistance, limited comparative data, ineffectiveness against molds, and cost.

Purpose of the Study:

• To review the use of fluconazole for prophylaxis and treatment in various transplant situations.
• To discuss the judicious application of fluconazole in light of potential challenges.

Main Methods:

• Review of existing literature on fluconazole use in transplant patients.
• Analysis of clinical data regarding efficacy, resistance, and comparative effectiveness.

Main Results:

• Fluconazole is effective in established indications for candidal infections.
• Challenges in transplant settings include potential resistance, lack of data, mold coverage gaps, and cost.
• Careful patient selection and established indications are crucial.

Conclusions:

• Judicious use of fluconazole in well-established indications is recommended for optimal patient therapy and to mitigate pathogen resistance.
• Further clinical trials are needed for new antifungal agents to guide rational prescribing in specific transplant scenarios.